rivaroxaban/rafarm 15mg film coated tablets
rafarm s.a. (0000009118) 12 korinthou str, athens, 154 51 - rivaroxaban - film coated tablets - 15mg - rivaroxaban (8000003442) 15mg
rivaroxaban/rafarm 15mg and 20mg film coated tablets
rafarm s.a. (0000009118) 12 korinthou str, athens, 154 51 - rivaroxaban; rivaroxaban - film coated tablets - 15mg and 20mg - rivaroxaban (8000003442) 15mg; rivaroxaban (8000003442) 20mg
rivaroxaban/rafarm 20mg film coated tablets
rafarm s.a. (0000009118) 12 korinthou str, athens, 154 51 - rivaroxaban - film coated tablets - 20mg - rivaroxaban (8000003442) 20mg
obergan f.c.tab 10mg/tab
demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - rivaroxaban - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 10mg/tab - rivaroxaban 10mg - rivaroxaban
obergan f.c.tab 20mg/tab
demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - rivaroxaban - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 20mg/tab - rivaroxaban 20mg - rivaroxaban
obergan f.c.tab 15mg/tab
demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - rivaroxaban - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 15mg/tab - rivaroxaban 15mg - rivaroxaban
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Αντιθρομβωτικοί παράγοντες - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
naxat 15mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - rivaroxaban - film coated tablets - 15mg - rivaroxaban (8000003442) 15mg
naxat 20mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - rivaroxaban - film coated tablets - 20mg - rivaroxaban (8000003442) 20mg
naxat 10mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - rivaroxaban - film coated tablets - 10mg - rivaroxaban (8000003442) 10mg